Wildcat Capital Management, LLC 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Wildcat Capital Management, LLC disclosed 6 US equity positions worth $168.3m in its Q2 2025 13F filing. The largest position was ULCC at 60.5% of the reported book, followed by RLX and TIC. Against the Q1 2025 filing, it opened 0 new positions, added to 0 and reduced 0 among the top 6 holdings.
What did Wildcat Capital Management, LLC own in Q2 2025? Top 6 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ULCC FRONTIER GROUP HLDGS INC | Industrials | 60.5% | $101.9m | 28,061,351 | 0% | held |
| 2 | RLX RLX TECHNOLOGY INC | Consumer Defensive | 23.7% | $39.9m | 18,046,195 | 0% | held |
| 3 | TIC ACUREN CORP | 9.8% | $16.6m | 1,500,000 | 0% | held | |
| 4 | URGN UROGEN PHARMA LTD | Healthcare | 4.0% | $6.8m | 495,606 | 0% | held |
| 5 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 1.9% | $3.1m | 2,920,787 | 0% | held |
| 6 | SILEXION THERAPEUTICS CORP | 0.1% | $91.9k | 113,428 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.